Article
Clinical Neurology
Simona Bonavita, Luigi Lavorgna, Hilary Worton, Susan Russell, Dominic Jack
Summary: The survey found that multiple sclerosis significantly impacts family planning decision making, with MS patients significantly less likely to have children compared to the general population. Some patients change their plans for timing of pregnancy and number of children due to the disease. Healthcare professionals are the primary source of information on family planning for MS patients.
FRONTIERS IN NEUROLOGY
(2021)
Review
Clinical Neurology
Francesca Washington, Dawn Langdon
Summary: Research shows that patients with multiple sclerosis often struggle with treatment adherence, influenced by factors such as age, gender, emotions, cognition, and treatment satisfaction. Targeted patient support programs should be developed to improve treatment compliance.
JOURNAL OF NEUROLOGY
(2022)
Article
Public, Environmental & Occupational Health
Anna Fragkoudi, Alice R. Rumbold, Luke E. Grzeskowiak
Summary: This study explored the experiences of Australian male and female patients with multiple sclerosis (MS) in relation to family planning. The findings revealed the need for consistent communication with healthcare professionals (HCPs) regarding pregnancy intentions and improvements in the quality and accessibility of resources and support services for addressing reproductive concerns. It is important to integrate family planning conversations into routine care planning for MS patients and provide contemporary resources to support these discussions.
PATIENT EDUCATION AND COUNSELING
(2023)
Article
Clinical Neurology
Massimo Filippi, Maria Pia Amato, Diego Centonze, Paolo Gallo, Claudio Gasperini, Matilde Inglese, Francesco Patti, Carlo Pozzilli, Paolo Preziosa, Maria Trojano
Summary: Early intervention with high-efficacy disease-modifying therapies (HE-DMTs) can significantly reduce inflammation and disease progression in patients with multiple sclerosis (MS), with acceptable long-term safety risks.
JOURNAL OF NEUROLOGY
(2022)
Review
Clinical Neurology
Hans-Peter Hartung, Sven G. Meuth, Deborah M. Miller, Giancarlo Comi
Summary: The review assesses the reasons for considering discontinuation of disease-modifying therapies in MS patients, finding that stopping treatment may be feasible for older individuals with stable disease. Prognostic factors have been identified, and several clinical scenarios provide rationale for stopping treatment. Recent evidence allows for a more precise weighing of risks against benefits.
CURRENT OPINION IN NEUROLOGY
(2021)
Review
Clinical Neurology
Fioravante Capone, Angela Albanese, Giorgia Quadri, Vincenzo Di Lazzaro, Emma Falato, Antonio Cortese, Laura De Giglio, Elisabetta Ferraro
Summary: Pregnancy-related issues and the use of disease-modifying therapies (DMTs) during pregnancy and breastfeeding in women with multiple sclerosis (MS) need to be carefully considered. Breastfeeding has benefits for both infants and mothers, but its protective role in MS is still debated. The potential transfer of DMTs into breastmilk and the resulting exposure to infants is a concern, leading to a difficult choice between breastfeeding and DMT resumption.
FRONTIERS IN NEUROLOGY
(2022)
Review
Clinical Neurology
Isabella Laura Simone, Carla Tortorella, Alma Ghirelli
Summary: Multiple sclerosis predominantly affects young women, impacting fertility, pregnancy, fetal outcome, and breastfeeding. The use of disease-modifying therapies has changed the natural history of the disease and perspectives on pregnancy.
FRONTIERS IN NEUROLOGY
(2021)
Article
Medical Informatics
I. E. H. Kremer, P. J. Jongen, S. M. A. A. Evers, E. L. J. Hoogervorst, W. I. M. Verhagen, M. Hiligsmann
Summary: A patient decision aid based on MCDA principles was developed to identify preferences of MS patients in treatment decisions, by studying patients and healthcare professionals' informational needs and opinions. The ultimate goal is to support the shared decision-making process.
BMC MEDICAL INFORMATICS AND DECISION MAKING
(2021)
Review
Clinical Neurology
Susana Otero-Romero, Alberto Ascherio, Christine Lebrun-Frenay
Summary: New evidence supports the lack of causal link between MS and vaccination, with consensus statements emphasizing the importance of starting vaccination early. Timing adjustments for vaccine administration are necessary to ensure safety and optimize vaccine responses in light of potential interference from DMDs. Patients on B-cell depleting therapies like Ocrelizumab are at risk of reduced immunogenicity to vaccines, highlighting the implications for upcoming SARS-CoV-2 vaccination.
CURRENT OPINION IN NEUROLOGY
(2021)
Article
Rehabilitation
Meheroz H. Rabadi, Kimberly Just, Chao Xu
Summary: This study aimed to determine the association between adherence to disease-modifying therapies (DMTs) and employment in patients with multiple sclerosis (MS). The results showed that patients who adhered to DMTs were more likely to be in paid employment, providing motivation for encouraging adherence.
DISABILITY AND REHABILITATION
(2022)
Review
Immunology
Georges Jalkh, Rachelle Abi Nahed, Gabrielle Macaron, Mary Rensel
Summary: In the past decade, the therapeutic options for multiple sclerosis have greatly expanded, with newer and more effective disease modifying therapies being increasingly used early in the disease course. Despite their advantages in controlling disease activity and improving long-term outcomes, these newer therapies come with safety concerns and monitoring requirements that highlight the need for periodic re-evaluation and adjustment of monitoring strategies for optimizing treatment safety in an individualized manner.
Article
Immunology
Yinxiang Wang, Jue Wang, Juan Feng
Summary: This article provides an update on pregnancy-related issues in women with multiple sclerosis, including general recommendations for management at each stage of pregnancy.
AUTOIMMUNITY REVIEWS
(2023)
Article
Clinical Neurology
Steve Simpson-Yap, Edward De Brouwer, Tomas Kalincik, Nick Rijke, Jan A. Hillert, Clare Walton, Gilles Edan, Yves Moreau, Tim Spelman, Lotte Geys, Tina Parciak, Clement Gautrais, Nikola Lazovski, Ashkan Pirmani, Amin Ardeshirdavanai, Lars Forsberg, Anna Glaser, Robert McBurney, Hollie Schmidt, Arnfin B. Bergmann, Stefan Braune, Alexander Stahmann, Rodden Middleton, Amber Salter, Robert J. Fox, Anneke van der Walt, Helmut Butzkueven, Raed Alroughani, Serkan Ozakbas, Juan Rojas, Ingrid van der Mei, Nupur Nag, Rumen Ivanov, Guilherme Sciascia do Olival, Alice Estavo Dias, Melinda Magyari, Doralina Brum, Maria Fernanda Mendes, Ricardo N. Alonso, Richard S. Nicholas, Johana Bauer, Anibal Sebastian Chertcoff, Anna Zabalza, Georgina Arrambide, Alexander Fidao, Giancarlo Comi, Liesbet Peeters
Summary: Using data from 12 sources in 28 countries, this study examined the characteristics of COVID-19 severity in people with MS, particularly those taking immunosuppressive therapies. The results showed that older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Additionally, rituximab was consistently associated with increased risk of hospitalization, ICU admission, and need for ventilation, while ocrelizumab was mainly associated with hospitalization and ICU admission.
Article
Clinical Neurology
Line Broch, Heidi Oyen Flemmen, Cecilia Smith Simonsen, Pal Berg-Hansen, Heidi Ormstad, Cathrine Brunborg, Elisabeth Gulowsen Celius
Summary: This study investigated the relationship between the use of disease-modifying treatment and fatigue in patients with multiple sclerosis. The results showed that there was no independent relationship between the use of disease-modifying treatment and fatigue.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Neurosciences
Eleonora Sgarlata, Clara Grazia Chisari, Simona Toscano, Chiara Finocchiaro, Salvatore Lo Fermo, Enrico Millefiorini, Francesco Patti
Summary: This study evaluated the effects of different disease-modifying therapies on the JCV index. The results showed that treatments with T and/or B cell depleting mechanisms significantly reduced the JCV index. These findings suggest potential new strategies for reducing the risk of PML.
CURRENT NEUROPHARMACOLOGY
(2022)